Harri Järveläinen

Co-Founder and CEO at Aivo Biosciences, Inc.

Presenter

Aivo Biosciences is a preclinical-stage biotech based in San Diego and Beijing (incorp. Nov 2024). We are developing highly optimized small molecules for neuropsychiatric and neurodegenerative diseases, with our potent and selective muscarinic receptor agonist lead compound for schizophrenia and dementia-related psychosis now ready for GLP tox. Management with years of experience in muscarinic agonist development, and a track record of taking assets from academia into the clinic & exit.